Westwater Resources Inc
Change company Symbol lookup
Select an option...
WWR Westwater Resources Inc
AGNPF Algernon Pharmaceuticals Inc
VNTR Venator Materials PLC
DVAX Dynavax Technologies Corp
GE General Electric Co
GTPBU Gores Technology Partners II Inc
IRBT iRobot Corp
NRG NRG Energy Inc
FRLAU Fortune Rise Acquisition Corp
BTBT Bit Digital Inc
Go

Industrials : Electrical Equipment | Small Cap Value
Company profile

Westwater Resources Inc. is a diversified energy materials developer. The Company holds battery-graphite development properties in Alabama. The Company’s projects include Coosa Graphite Project, Bama Mine Project, COOSA Graphite-Vanadium Project. The Company’s COOSA Graphite Project comprises of 42,000 acres (more than 65 square miles) and is a graphite project. It is located in western Coosa County, east-central Alabama, the United States of America (USA). The Bama Mine Project is located in Alabama Graphite Belt and comprises of 1,300 acres of land. The vanadium mineralization at the Coosa project occurs principally as the mineral roscoelite, a medium to dark green mica mineral that has been a global source for vanadium.

Postmarket

Last Trade
Delayed
$0.00
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$1.13
Day's Change
-0.06 (-5.04%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
1.22
Day's Low
1.13
Volume
(Light)
Volume:
282,783

10-day average volume:
361,457
282,783

COMPASS Pathways to participate in upcoming BTIG Biotechnology Conference and Canaccord Annual Growth Conference

8:00 am ET August 1, 2022 (Globe Newswire) Print

EQNX::TICKER_START (NASDAQ:CMPS), EQNX::TICKER_END COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in two upcoming events as follows:

A live audio webcast of each event will be accessible from the "Events" page of the Investors section of the COMPASS website. Each replay of the webcast will be accessible for 30 days following each event. For more information, please visit ir.compasspathways.com.

About COMPASS Pathways

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we have completed a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. This was the largest randomised, controlled, double-blind psilocybin therapy clinical trial ever conducted, and our topline data showed a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single high dose of COMP360 psilocybin with psychological support. We are also running a phase II clinical trial of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD). COMPASS is headquartered in London, UK, with offices in New York and San Francisco in the US. Our vision is a world of mental wellbeing. www.compasspathways.com

Availability of other information about COMPASS Pathways

Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Enquiries

Media: Amy Lawrence, amy@compasspathways.com, +44 7813 777 919

Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324

https://ml-eu.globenewswire.com/media/e61ab9b9-87f6-4418-b0d9-2fd1a7f5f90c/small/compass-positive-tagline-01-png.png

https://ml-eu.globenewswire.com/media/e61ab9b9-87f6-4418-b0d9-2fd1a7f5f90c/small/compass-positive-tagline-01-png.png

comtex tracking

COMTEX_411347219/2010/2022-08-01T08:00:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.